Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib + trastuzumab + mFOLFOX6 versus standard first-line mFOLFOX6-based therapy in HER2-positive metastatic colorectal cancer
2021-002672-40Phase 3Active
- Sponsor
- Seagen Inc.
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tucatinib, trastuzumab, mFOLFOX6, cetuximab and bevacizumab in colorectal cancer (CRC) (2 arms), sponsored by Seagen Inc. Primary endpoint: Progression-free survival. Started Apr 2022; status: active.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2021-002672-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002672-40.